# Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer

> **NCT00601796** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 24 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** Vaccine Treatment
- **DRUG:** Cyclophosphamide
- **DRUG:** All-trans retinoic acid (ATRA)

## Key facts

- **NCT ID:** NCT00601796
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601796, "Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00601796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*